Kenvue (KVUE)

• Market cap: $41.7B
• 1 day: 0.74%
• 5 days: -2.51%
• 1 month: -8.45%
• 3 months: -5.43%
• 6 months: 15.55%
• Year to date: 0.93%
• 1 year: 3.91%
• 5 years: -19.07%
• 10 years: -19.07%
• Sector: Materials
• Industry: Perfumes, Cosmetics & Other Toilet Preparations

About: Kenvue is the world's largest pure-play consumer health company by sales, generating $15 billion in annual revenue. Formerly known as Johnson & Johnson's consumer segment, Kenvue spun off and went public in May 2023. It operates in a variety of silos within consumer health, such as cough, cold and allergy care, pain management, face and body care, and oral care, as well as women's health. Its portfolio includes a wide array of some of the most well-known brands in the space, including Tylenol, Listerine, Johnson's, Aveeno, and Neutrogena. Despite playing in a fragmented industry with intense competition and ever-changing consumer preferences, many of Kenvue's brands are the global leader in their respective segment thanks to their strong brand power.

Employees: 22,000

Fund manager confidence

Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)

26% more capital invested

Capital invested by funds: $34.5B [Q2] → $43.5B (+$9.01B) [Q3]

17% more call options, than puts

Call options by funds: $297M | Put options by funds: $253M

1% more first-time investments, than exits

New positions opened: 121 | Existing positions closed: 120

0% more funds holding

Funds holding: 984 [Q2] → 985 (+1) [Q3]

0.68% less ownership

Funds ownership: 98.97% [Q2] → 98.29% (-0.68%) [Q3]

10% less repeat investments, than reductions

Existing positions increased: 369 | Existing positions reduced: 409

7% less funds holding in top 10

Funds holding in top 10: 15 [Q2] → 14 (-1) [Q3]

Research analyst outlook

6 Wall Street Analysts provided 1 year price targets over the past 3 months

• Low target: $21 4% downside
• Avg. target: $25 13% upside
• High target: $27 24% upside

6 analyst ratings

• positive: 3 50%
• neutral: 3 50%
• negative: 0 0%

Deutsche Bank Steve Powers 63% 1-year accuracy 12 / 19 met price target	10% upside $24	Hold Downgraded	12 Dec 2024
B of A Securities Anna Lizzul 33% 1-year accuracy 3 / 9 met price target	24% upside $27	Buy Maintained	22 Oct 2024
JP Morgan Andrea Teixeira 45% 1-year accuracy 24 / 53 met price target	15% upside $25	Overweight Maintained	11 Oct 2024
Jefferies Keith Devas 0% 1-year accuracy 0 / 1 met price target	24% upside $27	Buy Initiated	24 Sept 2024
RBC Capital Nik Modi 31% 1-year accuracy 11 / 36 met price target	10% upside $24	Sector Perform Downgraded	24 Sept 2024